BioWorld

Dec. 1, 2006

Durect, Nycomed Agree On Pain Drug Marketing Deal

Shares of Durect Corp. rose nearly 50 percent in after-close trading Wednesday based on a $202 million marketing deal between the Cupertino, Calif.-based company and Roskilde, Denmark-based Nycomed A/S. (BioWorld Today) Read More

Still Silent, Concert Pharma Raising $48.5M In Series B

Biota, Boehringer Partner HCV Nucleoside Program For $102M

Cancer Company Xanthus Adding $25M Via Series B

Other News To Note

Clinic Roundup

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for Dec. 17, 2024.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for December 17, 2024.

Second insulin receptor offers new therapeutic avenues

BioWorld Science

Investigators at the Helmholtz Institute have shown that inceptor, an inhibitor of the insulin signaling pathway, acted by binding insulin and targeting it for...

Experimental mRNA gene therapy suppresses preeclampsia in mice

BioWorld MedTech

A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...

Drug duo to Repare lack in gyno cancers? Phase I shows promise

BioWorld

Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...